Cingulate Q1 net loss $3.8M, cash $9.5M; NDA submission for CTx-1301 on track mid-2025

Cingulate Inc.

2025-Q1 EPS reported -$1.04

Net loss of $3.8M ($1.04 per share) for Q1 2025, compared to $3.0M in Q1 2024.
Cash and equivalents $9.5M at March 31, 2025; cash runway into Q4 2025 beyond NDA submission.
Pre-NDA meeting with FDA completed April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.
Received $3M non-dilutive grant from private foundation to accelerate CTx-2103 (buspirone) anxiety asset.
Working capital $4.9M at Q1 end, down from $7.7M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.